GOSS - Gossamer Bio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
16.43
+0.33 (+2.02%)
At close: 4:00PM EDT

16.43 0.00 (0.00%)
After hours: 4:31PM EDT

Stock chart is not supported by your current browser
Previous Close16.10
Open16.03
Bid16.44 x 1200
Ask16.46 x 800
Day's Range15.73 - 16.60
52 Week Range14.63 - 25.06
Volume200,281
Avg. Volume453,113
Market Cap1.083B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-5.95
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.00
Trade prices are not sourced from all markets
  • Weekly CEO Buys Highlight
    GuruFocus.com

    Weekly CEO Buys Highlight

    Insiders invest in Gossamer Bio, Heron Therapeutics and Athenex Continue reading...

  • Business Wire

    Gossamer Bio Announces Participation in the 2019 Cantor Global Healthcare Conference

    Gossamer Bio, Inc. (GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila Gujrathi, M.D., Chief Executive Officer and Co-Founder, will present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2 at 7:45 a.m. ET. Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology.

  • Seth Klarman Further Increases Translate Bio Stake
    GuruFocus.com

    Seth Klarman Further Increases Translate Bio Stake

    Baupost leader ups bet on biotech company that focuses on genetic diseases Continue reading...

  • Business Wire

     Gossamer Bio Announces the Departure of Dr. Otello Stampacchia from its Board of Directors

    Gossamer Bio, Inc. (GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced Otello Stampacchia, Ph.D., of Omega Funds, resigned from the company’s Board of Directors. Dr. Stampacchia has served as a director of the company since January 2018, and Omega Funds was the founding seed investor of Gossamer. “The support and resources we received from Otello and Omega were critical to launching Gossamer in January 2018,” said Faheem Hasnain, Chairman of Gossamer.

  • Baupost's Seth Klarman Dives Further Into Translate Bio
    GuruFocus.com

    Baupost's Seth Klarman Dives Further Into Translate Bio

    Guru adds to position in biotech company that focuses on genetic diseases Continue reading...

  • Implied Volatility Surging for Gossamer Bio (GOSS) Stock Options
    Zacks

    Implied Volatility Surging for Gossamer Bio (GOSS) Stock Options

    Investors need to pay close attention to Gossamer Bio (GOSS) stock based on the movements in the options market lately.

  • Seth Klarman's Small Biotech Holdings
    GuruFocus.com

    Seth Klarman's Small Biotech Holdings

    A look at some of the guru's smaller, overlooked positions Continue reading...

  • Gossamer Bio, Inc. (GOSS) Q2 2019 Earnings Call Transcript
    Motley Fool

    Gossamer Bio, Inc. (GOSS) Q2 2019 Earnings Call Transcript

    GOSS earnings call for the period ending June 30, 2019.

  • Read This Before Selling Gossamer Bio, Inc. (NASDAQ:GOSS) Shares
    Simply Wall St.

    Read This Before Selling Gossamer Bio, Inc. (NASDAQ:GOSS) Shares

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

  • Seth Klarman's Favorite Biotech Positions
    GuruFocus.com

    Seth Klarman's Favorite Biotech Positions

    Some ideas from Baupost's pharmaceutical portfolio

  • Seth Klarman Introduces 7 New Positions in 1st Quarter
    GuruFocus.com

    Seth Klarman Introduces 7 New Positions in 1st Quarter

    Baupost’s new positions include companies formed by Disney-Fox merger

  • Gossamer Bio, Inc. (GOSS) Q1 2019 Earnings Call Transcript
    Motley Fool

    Gossamer Bio, Inc. (GOSS) Q1 2019 Earnings Call Transcript

    GOSS earnings call for the period ending March 31, 2019.

  • Associated Press

    Gossamer Bio: 1Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 90 cents. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment ...

  • Business Wire

    Gossamer Bio Announces First Quarter 2019 Financial Results

    – Multiple trial initiations and data readouts expected in the next 12 months –

  • How Much Of Gossamer Bio, Inc. (NASDAQ:GOSS) Do Insiders Own?
    Simply Wall St.

    How Much Of Gossamer Bio, Inc. (NASDAQ:GOSS) Do Insiders Own?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Business Wire

    Gossamer Bio to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 14, 2019

    Gossamer Bio, Inc.  , a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its first quarter 2019 financial results on Tuesday, May 14, 2019.

  • Business Wire

    Gossamer Bio Secures Debt Facility for up to $150 Million

    Gossamer Bio, Inc. (GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced it entered into a five-year senior debt facility led by MidCap Financial (MidCap). The lenders under the debt facility, including affiliates of MidCap, will make available to Gossamer an aggregate principal amount up to $150 million. The facility provides the company with access to capital for general corporate purposes and to support the development of Gossamer’s development candidates.

  • Business Wire

    Gossamer Bio Announces Participation in Bank of America Merrill Lynch Health Care Conference 2019

    Gossamer Bio, Inc. (GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila Gujrathi, M.D., Chief Executive Officer and Co-Founder, will participate in a fireside chat at the Bank of America Merrill Lynch Health Care Conference on Tuesday, May 14 at 1:00 p.m. PT. Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology.

  • Business Wire

    Gossamer Bio Announces 2018 Annual Financial Results

    Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the year ended December 31, 2018 and provided an update on recent corporate developments.

  • Business Wire

    Gossamer Bio Announces Participation in Upcoming Investor Conferences

    Gossamer Bio, Inc.  , a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of

  • GuruFocus.com

    Gossamer Aims to Be Genentech Clone

    The executive chairman of Gossamer Bio (NASDAQ: GOSS) has a lofty goal for the company: Be the next version of Genentech, the biotechnology giant that is now a subsidiary of Roche (OTCPK: RHHBY). The odds are high, but Faheem Hasnain's track record suggests he may have assembled just the team to make that dream a reality. If the company comes anywhere near being the next Genentech, the share price will prove to be the biggest bargain since the purchase of Alaska.

  • Business Wire

    Gossamer Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    Gossamer Bio, Inc. (GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the closing of its previously announced initial public offering of 19,837,500 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 2,587,500 additional shares, at a price to the public of $16.00 per share. Including the option exercise, the aggregate gross proceeds to Gossamer Bio from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were $317.4 million. BofA Merrill Lynch, SVB Leerink, Barclays and Evercore ISI acted as joint book-running managers for the offering.